nach oben

Wiener klinische Wochenschrift

Erschienen in:

20.07.2018 | review article

Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease—a review

verfasst von: Univ.-Cpz. Dr. Hannes F. Alber, Univ.-Prof. Dr. Kurt Huber

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2018

Einloggen, um Zugang zu erhalten

Summary

Duration and compostion of dual antiplatelet therapy has been increasingly changed within the past few years as also indicated in the firmer ESC guidelines. The current manuscript summarizes the most important changes in dual antiplatelet therapy as shown by a recent ESC position paper and offers quick insight into these new developments.

Vorheriger Artikel Transcatheter mitral valve repair using the MitraClip: which patients benefit most?

Nächster Artikel Lowering blood pressure in primary care in Vienna (LOW-BP-VIENNA)

Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213–60. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the EuropeESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.an Association for Cardio-Thoracic Surgery (EACTS).CrossRefPubMed

Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.CrossRefPubMed

Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).CrossRefPubMed

Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541–619. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).CrossRefPubMed

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRefPubMed

Holcomb CN, Graham LA, Richman JS, Itani KM, Maddox TM, Hawn MT. The incremental risk of coronary stents on postoperative adverse events: a matched cohort study. Ann Surg. 2016;263:924–30.CrossRefPubMed

Storey RF, Bliden KP, Patil SB, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56(3):185–93.CrossRefPubMed

Gherli R, Mariscalco G, Dalén M, et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol. 2016;1:921–8.CrossRefPubMed

PEGASUS-TIMI 54 Steering Committee and Investigators, Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.CrossRef

10.

DAPT Study Investigators, Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–66.CrossRef

11.

Ziada KM, Abdel-Latif AK, Charnigo R, et al. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: a systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2016;87(4):722–32.CrossRefPubMed

12.

Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163–70.CrossRefPubMed

13.

Lee KS, Lee JZ, Hsu CH, et al. Temporal trends in strut-level optical coherence tomography evaluation of coronary stent coverage: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2016;88(7):1083–93.CrossRefPubMed

14.

Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–47.CrossRefPubMed

15.

Morice MC, Talwar S, Gaemperli O, et al. Drug-coated versus bare-metal stents for elderly patients: a predefined sub-study of the LEADERS FREE trial. Int J Cardiol. 2017;243(15):110–5.CrossRefPubMed

16.

Naber CK, Urban P, Ong PJ, et al. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a leaders free ACS sub-study. Eur Heart J. 2017;38(13):961–9.PubMed

17.

Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–34.CrossRefPubMed

18.

Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–77. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).CrossRefPubMed

19.

Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.CrossRefPubMed

20.

Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.CrossRefPubMed

Titel: Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease—a review
verfasst von: Univ.-Cpz. Dr. Hannes F. Alber
Univ.-Prof. Dr. Kurt Huber
Publikationsdatum: 20.07.2018
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 23-24/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-018-1357-5

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 23-24/2018

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding

Bernhard Grubmüller ist "Researcher of the Month"

Intuity™ aortic valve thrombosis

Veranstaltungstipps

To the next decade

Transcatheter mitral valve repair using the MitraClip: which patients benefit most?